Enumeral Biomedical Holdings Inc
Enumeral Biomedical — BiopharmAmerica 2015
19 slides from Enumeral Biomedical's conference presentation, Sep 17, 2015
Slide 1: BiopharmAmerica 2015
BiopharmAmerica 2015 September 17, 2015
Slide 2: Forward Looking Statements
Forward Looking Statements OTC QB: ENUM THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT ARE BASED ON THE COMPANY’S CURRENT EXPECTATIONS, ASSUMPTIONS, ESTIMATES AND PROJECTIONS ABOUT THE COMPANY AND THE PHARMACEUTICAL INDUSTRY. THE COMPANY MAKES NO REPRESENTATIONS ABOUT THE ACCURACY OF SUC
Slide 3: Enumeral Mission
EnumeralMission 3 A biopharma company developing potential ‘best- in-class’ antibodies against both proven and new targets using a proprietary immuno-oncology profiling technology.
Slide 4: Enumeral's Differentiated Approach
Enumeral’sDifferentiated Approach 4 Create broad antibody diversity Measure antibody function using our ‘Human immune system on a chip’ platform Select best-in-class candidates that modulate desired immune effector cells
Slide 5: Discovery and Profiling Processes
Discovery and Profiling Processes 5
Slide 6: Enumeral Platform
EnumeralPlatform 6 Microwell device with 84,672 50m wells
Slide 7: Platform Enables All IO Entry Points
Platform Enables All IO Entry Points 7
Slide 8: Functional Diversity: Potential for Best-in-Class Pharmacologic and MOA Differentiation
Functional Diversity: Potential for Best-in-Class Pharmacologic and MOA Differentiation 8 Screen 1-12 Heavy chain AA sequences from PD1 N= 159 sequences shown; 28 families of antibodies OPDIVO® KEYTRUDA® Pidilizumab • 6 antibodies (from different clades) chosen for small scale production • Ability t
Slide 9: Differential T-Cell Activation
Differential T-Cell Activation 9 0 10 20 30 40 50 60 70 80 % P o s i t i v e C e l l s CD8+ IFN?+ CD4+ IFN?+ CD8+ TNFa+
Slide 10: Antigen Recall Assay
~ Antigen Recall Assay ~ 7000 D4- HC3+LC1 a -= D4-HC1+LC3 —« D4-HC3+LC3 6000 —- C8-HC1+LC1 -e C8-HC1+LC3 -= C8-HC2+LC1 == 5000 Isotype Control 5000 E Nivolumab 25001 NN o4 0.001 0.01 0.1 1 10 100 Antibody Concentration (11.g/mL) IFNy (pg/ml) ENUSERAL
Slide 11: Mixed Lymphocyte Reaction (6 days)
Mixed Lymphocyte Reaction (6 days) 11
Slide 12: Consistent, repeatable diversity for additional checkpoint targets
Our approach to discovery has resulted in consistent, repeatable levels of diversity for additional checkpoint targets 12
Slide 13: TIM-3 Program Diversity
13 TIM-3 Program Diversity • CDR3 cladistics • 114 sequences • Greenboxes indicate a confirmed binder (ELISA) *indicates confirmed cell- based binder * * Screen1: 100600-100605 Screen4: 100646-100671 Screen6: 100730-100734 Screen12: 100810-100816 Screen13: 100874-100881 Screen14: 100928-100931 Scree
Slide 14: LAG-3 Program Diversity
14 LAG-3 Program Diversity • CDR3 cladistics shown • 64 sequences CONFIDENTIAL
Slide 15: Why Diversity Matters
Why Diversity Matters: • TIM-3 biology much more complex than any other I/O target: – Ligands: – Galectin-9 – Phosphatidylserine – CEACAM1 • Correct epitope is unknown for therapeutic TIM-3 blockade • TIM-3 also a marker for cancer progression 15 Anderson et al 2007 Immunity
Slide 16: Tissue Profiling: Human Translational Link Between Discovery and Development
Tissue Profiling: Human Translational Link Between Discovery and Development 16 Use of human tissues serves as a bridge between mAbfunction in vitro and cellular function in tumors in relevant indications
Slide 17: Tumor Profiling at the Single Cell Level
Tumor Profiling at the Single Cell Level 17
Slide 18: Indication Mapping - TIM3
O v a r i a n R e n a l C a n c e r A v a s t i n R a f / M E K i PD1 Blockade Indication Mapping - T I M 3
Slide 19: Conclusions
Conclusions • Our PD1 program gives us an independent benchmark therapeuticfor partnering in immuno-oncology • Our pipeline places us in an ideal position to further combination IO strategies in diverse indications with urgent unmet need • Our single-cell analysis platform will allow us to better un